Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 7/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 4/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | WNT1 | P04628 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.36 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6714035 | 0.89 | ROCK2 (0.36) | TDP2KDM1AROCK2MAOARCOR1 | |
| SCHEMBL6713419 | 0.89 | SRD5A2 (0.44) | SRD5A2KDM1AMAOAWNT1DYRK1A | |
| SCHEMBL6712525 | 0.89 | SRD5A2 (0.44) | SRD5A2KDM1AMAOARCOR1TSHR | |
| SCHEMBL6708021 | 0.88 | MAPT (0.41) | TDP2KDM1AROCK2MAOATSHR | |
| SCHEMBL6714039 | 0.87 | KDM1A (0.44) | KDM1AROCK2MAOARCOR1 | |
| SCHEMBL6707752 | 0.86 | KDM1A (0.43) | KDM1AROCK2MAOARCOR1 | |
| SCHEMBL6918878 | 0.85 | TDP2 (0.45) | TDP2SRD5A2KDM1AROCK2MAOA | |
| SCHEMBL6709131 | 0.85 | PPIA (0.39) | TDP2SRD5A2KDM1AMET | |
| SCHEMBL6708703 | 0.85 | ROCK2 (0.35) | TDP2KDM1AROCK2MAOARCOR1 | |
| SCHEMBL6711975 | 0.85 | TRPA1 (0.46) | KDM1AROCK2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
| WO-2004018461-A2 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | TDP2 3788/4885SRD5A2 873/4885KDM1A 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.